Incidence of neoplasia in Diamond Blackfan anemia: A report from the Diamond Blackfan anemia registry

Adrianna Vlachos, Philip S. Rosenberg, Eva Atsidaftos, Blanche P. Alter, Jeffrey M. Lipton

Research output: Contribution to journalArticle

Abstract

Diamond Blackfan anemia (DBA) is an inherited bone marrow failure syndrome characterized by red cell aplasia and congenital anomalies. A predisposition to cancer has been suggested but not quantified by case reports. The DBA Registry of North America (DBAR) is the largest established DBA patient cohort, with prospective follow-up since 1991. This report presents the first quantitative assessment of cancer incidence in DBA. Among 608 patients with 9458 person-years of follow-up, 15 solid tumors, 2 acute my-eloid leukemias, and 2 cases of myelodys-plastic syndrome were diagnosed at a median age of 41 years in patients who had not received a bone marrow transplant. Cancer incidence in DBA was significantly elevated. The observed-to-expected ratio for all cancers combined was 5.4 (P <.05); significant observed-to-expected ratios were 287 for myelodys-plastic syndrome, 28 for acute myeloid leukemia, 36 for colon carcinoma, 33 for osteogenic sarcoma, and 12 for female genital cancers. The median survival was 56 years, and the cumulative incidence of solid tumor/leukemia was approximately 20% by age 46 years. As in Fanconi anemia and dyskeratosis congenita, DBA is both an inherited bone marrow failure syndrome and a cancer predisposition syndrome; cancer risks appear lower in DBA than in Fanconi anemia or dyskerato-sis congenita. This trial was registered at www.clinicaltrials.gov as #NCT00106015.

Original languageEnglish (US)
Pages (from-to)3815-3819
Number of pages5
JournalBlood
Volume119
Issue number16
DOIs
StatePublished - Apr 19 2012
Externally publishedYes

Fingerprint

Diamond-Blackfan Anemia
Diamond
Registries
Incidence
Neoplasms
Bone
Fanconi Anemia
Tumors
Plastics
Leukemia
Transplants
Dyskeratosis Congenita
Osteosarcoma
North America
Acute Myeloid Leukemia
Cells
Colon
Bone Marrow

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Vlachos, A., Rosenberg, P. S., Atsidaftos, E., Alter, B. P., & Lipton, J. M. (2012). Incidence of neoplasia in Diamond Blackfan anemia: A report from the Diamond Blackfan anemia registry. Blood, 119(16), 3815-3819. https://doi.org/10.1182/blood-2011-08-375972

Incidence of neoplasia in Diamond Blackfan anemia : A report from the Diamond Blackfan anemia registry. / Vlachos, Adrianna; Rosenberg, Philip S.; Atsidaftos, Eva; Alter, Blanche P.; Lipton, Jeffrey M.

In: Blood, Vol. 119, No. 16, 19.04.2012, p. 3815-3819.

Research output: Contribution to journalArticle

Vlachos, A, Rosenberg, PS, Atsidaftos, E, Alter, BP & Lipton, JM 2012, 'Incidence of neoplasia in Diamond Blackfan anemia: A report from the Diamond Blackfan anemia registry', Blood, vol. 119, no. 16, pp. 3815-3819. https://doi.org/10.1182/blood-2011-08-375972
Vlachos, Adrianna ; Rosenberg, Philip S. ; Atsidaftos, Eva ; Alter, Blanche P. ; Lipton, Jeffrey M. / Incidence of neoplasia in Diamond Blackfan anemia : A report from the Diamond Blackfan anemia registry. In: Blood. 2012 ; Vol. 119, No. 16. pp. 3815-3819.
@article{d6df58113f1c4f139ea190d789ee96b5,
title = "Incidence of neoplasia in Diamond Blackfan anemia: A report from the Diamond Blackfan anemia registry",
abstract = "Diamond Blackfan anemia (DBA) is an inherited bone marrow failure syndrome characterized by red cell aplasia and congenital anomalies. A predisposition to cancer has been suggested but not quantified by case reports. The DBA Registry of North America (DBAR) is the largest established DBA patient cohort, with prospective follow-up since 1991. This report presents the first quantitative assessment of cancer incidence in DBA. Among 608 patients with 9458 person-years of follow-up, 15 solid tumors, 2 acute my-eloid leukemias, and 2 cases of myelodys-plastic syndrome were diagnosed at a median age of 41 years in patients who had not received a bone marrow transplant. Cancer incidence in DBA was significantly elevated. The observed-to-expected ratio for all cancers combined was 5.4 (P <.05); significant observed-to-expected ratios were 287 for myelodys-plastic syndrome, 28 for acute myeloid leukemia, 36 for colon carcinoma, 33 for osteogenic sarcoma, and 12 for female genital cancers. The median survival was 56 years, and the cumulative incidence of solid tumor/leukemia was approximately 20{\%} by age 46 years. As in Fanconi anemia and dyskeratosis congenita, DBA is both an inherited bone marrow failure syndrome and a cancer predisposition syndrome; cancer risks appear lower in DBA than in Fanconi anemia or dyskerato-sis congenita. This trial was registered at www.clinicaltrials.gov as #NCT00106015.",
author = "Adrianna Vlachos and Rosenberg, {Philip S.} and Eva Atsidaftos and Alter, {Blanche P.} and Lipton, {Jeffrey M.}",
year = "2012",
month = "4",
day = "19",
doi = "10.1182/blood-2011-08-375972",
language = "English (US)",
volume = "119",
pages = "3815--3819",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "16",

}

TY - JOUR

T1 - Incidence of neoplasia in Diamond Blackfan anemia

T2 - A report from the Diamond Blackfan anemia registry

AU - Vlachos, Adrianna

AU - Rosenberg, Philip S.

AU - Atsidaftos, Eva

AU - Alter, Blanche P.

AU - Lipton, Jeffrey M.

PY - 2012/4/19

Y1 - 2012/4/19

N2 - Diamond Blackfan anemia (DBA) is an inherited bone marrow failure syndrome characterized by red cell aplasia and congenital anomalies. A predisposition to cancer has been suggested but not quantified by case reports. The DBA Registry of North America (DBAR) is the largest established DBA patient cohort, with prospective follow-up since 1991. This report presents the first quantitative assessment of cancer incidence in DBA. Among 608 patients with 9458 person-years of follow-up, 15 solid tumors, 2 acute my-eloid leukemias, and 2 cases of myelodys-plastic syndrome were diagnosed at a median age of 41 years in patients who had not received a bone marrow transplant. Cancer incidence in DBA was significantly elevated. The observed-to-expected ratio for all cancers combined was 5.4 (P <.05); significant observed-to-expected ratios were 287 for myelodys-plastic syndrome, 28 for acute myeloid leukemia, 36 for colon carcinoma, 33 for osteogenic sarcoma, and 12 for female genital cancers. The median survival was 56 years, and the cumulative incidence of solid tumor/leukemia was approximately 20% by age 46 years. As in Fanconi anemia and dyskeratosis congenita, DBA is both an inherited bone marrow failure syndrome and a cancer predisposition syndrome; cancer risks appear lower in DBA than in Fanconi anemia or dyskerato-sis congenita. This trial was registered at www.clinicaltrials.gov as #NCT00106015.

AB - Diamond Blackfan anemia (DBA) is an inherited bone marrow failure syndrome characterized by red cell aplasia and congenital anomalies. A predisposition to cancer has been suggested but not quantified by case reports. The DBA Registry of North America (DBAR) is the largest established DBA patient cohort, with prospective follow-up since 1991. This report presents the first quantitative assessment of cancer incidence in DBA. Among 608 patients with 9458 person-years of follow-up, 15 solid tumors, 2 acute my-eloid leukemias, and 2 cases of myelodys-plastic syndrome were diagnosed at a median age of 41 years in patients who had not received a bone marrow transplant. Cancer incidence in DBA was significantly elevated. The observed-to-expected ratio for all cancers combined was 5.4 (P <.05); significant observed-to-expected ratios were 287 for myelodys-plastic syndrome, 28 for acute myeloid leukemia, 36 for colon carcinoma, 33 for osteogenic sarcoma, and 12 for female genital cancers. The median survival was 56 years, and the cumulative incidence of solid tumor/leukemia was approximately 20% by age 46 years. As in Fanconi anemia and dyskeratosis congenita, DBA is both an inherited bone marrow failure syndrome and a cancer predisposition syndrome; cancer risks appear lower in DBA than in Fanconi anemia or dyskerato-sis congenita. This trial was registered at www.clinicaltrials.gov as #NCT00106015.

UR - http://www.scopus.com/inward/record.url?scp=84860338982&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860338982&partnerID=8YFLogxK

U2 - 10.1182/blood-2011-08-375972

DO - 10.1182/blood-2011-08-375972

M3 - Article

C2 - 22362038

AN - SCOPUS:84860338982

VL - 119

SP - 3815

EP - 3819

JO - Blood

JF - Blood

SN - 0006-4971

IS - 16

ER -